• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Integra LifeSciences Holdings Corporation

    5/9/25 2:16:33 PM ET
    $IART
    Medical/Dental Instruments
    Health Care
    Get the next $IART alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Integra LifeSciences Holdings Corp

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    457985208

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    457985208


    1Names of Reporting Persons

    Invesco Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    BERMUDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    4,065,241.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    4,111,700.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,111,700.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.3 %
    12Type of Reporting Person (See Instructions)

    HC, IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Integra LifeSciences Holdings Corp
    (b)Address of issuer's principal executive offices:

    1100 Campus Road, Princeton, NJ 08540
    Item 2. 
    (a)Name of person filing:

    Invesco Ltd. ("Invesco Ltd.")
    (b)Address or principal business office or, if none, residence:

    1331 Spring Street NW, Suite 2500, Atlanta, GA 30309
    (c)Citizenship:

    Bermuda
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    457985208
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Invesco Ltd., in its capacity as a parent holding company to its investment advisers, may be deemed to beneficially own 4,111,700 shares of the Issuer which are held of record by clients of Invesco Ltd.
    (b)Percent of class:

    5.3  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    4,065,241

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    4,111,700

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    However, no one individual has greater than 5% economic ownership. The shareholders of the Fund have the right to receive or the power to direct the receipt of dividends and proceeds from the sale of securities listed above.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Invesco Advisers, Inc. Invesco Capital Management LLC
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Invesco Ltd.
     
    Signature:Robert R. Leveille
    Name/Title:Global Head of Compliance
    Date:05/09/2025
    Get the next $IART alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IART

    DatePrice TargetRatingAnalyst
    3/31/2025Hold → Buy
    Argus
    12/2/2024$25.00 → $20.00Underweight
    Morgan Stanley
    10/7/2024Sell → Neutral
    BTIG Research
    7/30/2024$22.00Neutral → Sell
    BTIG Research
    7/30/2024$30.00 → $23.00Neutral → Sell
    Citigroup
    5/7/2024Outperform → Perform
    Oppenheimer
    5/7/2024$45.00 → $25.00Overweight → Equal Weight
    Wells Fargo
    4/3/2024$38.00Sell → Neutral
    Citigroup
    More analyst ratings

    $IART
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Integra LifeSciences Holdings Corporation

      SC 13G - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

      11/12/24 5:20:30 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation

      SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

      11/12/24 12:54:20 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation

      SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

      8/12/24 10:06:35 AM ET
      $IART
      Medical/Dental Instruments
      Health Care

    $IART
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Legal Officer & Sec Schwartz Eric covered exercise/tax liability with 2,718 shares, decreasing direct ownership by 5% to 56,020 units (SEC Form 4)

      4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

      3/13/25 4:30:51 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • EVP & CHIEF FINANCIAL OFFICER Knight Lea Daniels covered exercise/tax liability with 1,655 shares and was granted 20,859 shares, increasing direct ownership by 46% to 61,139 units (SEC Form 4)

      4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

      3/13/25 4:30:10 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • SVP, Fin & Princ Acct Officer Mosebrook Jeffrey covered exercise/tax liability with 443 shares and was granted 5,514 shares, increasing direct ownership by 14% to 40,882 units (SEC Form 4)

      4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

      3/13/25 4:28:33 PM ET
      $IART
      Medical/Dental Instruments
      Health Care

    $IART
    Leadership Updates

    Live Leadership Updates

    See more
    • Jan De Witte joins GHO Capital as Operating Partner

      Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr

      2/11/25 4:30:00 AM ET
      $IART
      $RMD
      Medical/Dental Instruments
      Health Care
    • Integra LifeSciences Announces Appointment of Mojdeh Poul as President and Chief Executive Officer

      PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that its board of directors has appointed Mojdeh Poul as the new president and chief executive officer, effective January 6, 2025. Ms. Poul will also join the Integra board when she assumes the role. She will succeed Jan De Witte, who will remain president and CEO until January 6, 2025. Stuart Essig will remain executive chairman of Integra for a limited period of time before returning to his prior role as non-executive chairman. "The board and I are thrilled to welcome Mojdeh as Integra's next president and CEO," sa

      11/4/24 6:00:00 AM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer

      Brings proven leadership and successful track record to Halda as the company enters the next stage of growth as clinical-stage company Halda Therapeutics, a biotechnology company developing a novel class of cancer therapies called RIPTAC™ (Regulated Induced Proximity TArgeting Chimeras) therapeutics, today announced that it has appointed Christian Schade as President and Chief Executive Officer and a member of the Board of Directors. Chris brings more than 20 years of public and private pharmaceutical and biotechnology industry experience, including building, financing and leading biotechnology companies through the clinical stages of pipeline development and formation of value-creating de

      10/1/24 8:30:00 AM ET
      $APRE
      $IART
      $OMGA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)

    $IART
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Integra LifeSciences Holdings Corporation

      SCHEDULE 13G - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

      5/9/25 2:16:33 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Integra LifeSciences Holdings Corporation

      10-Q - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)

      5/5/25 4:07:05 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Integra LifeSciences Holdings Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)

      5/5/25 6:45:23 AM ET
      $IART
      Medical/Dental Instruments
      Health Care

    $IART
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Integra upgraded by Argus

      Argus upgraded Integra from Hold to Buy

      3/31/25 8:28:08 AM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Morgan Stanley initiated coverage on Integra with a new price target

      Morgan Stanley initiated coverage of Integra with a rating of Underweight and set a new price target of $20.00 from $25.00 previously

      12/2/24 8:17:21 AM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Integra upgraded by BTIG Research

      BTIG Research upgraded Integra from Sell to Neutral

      10/7/24 7:56:40 AM ET
      $IART
      Medical/Dental Instruments
      Health Care

    $IART
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Essig Stuart bought $1,499,979 worth of shares (52,641 units at $28.49), increasing direct ownership by 12% to 487,922 units (SEC Form 4)

      4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

      5/24/24 4:08:19 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Hill Barbara B bought $995,816 worth of shares (36,350 units at $27.40) (SEC Form 4)

      4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

      5/22/24 4:09:18 PM ET
      $IART
      Medical/Dental Instruments
      Health Care

    $IART
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Integra LifeSciences Reports First Quarter 2025 Financial Results

      PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2025. First Quarter 2025 Highlights First quarter revenues of $382.7 million increased 3.7% on a reported basis and decreased 3.5% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $(0.33), compared to $(0.04) in the prior year; adjusted earnings per diluted share of $0.41, compared to $0.55 in the prior year.Reaffirming full-year 2025 revenue guidance range and updating adjusted EPS guidance to account for the impact

      5/5/25 6:30:00 AM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Integra LifeSciences to Host First Quarter 2025 Financial Results Conference Call on May 5, 2025

      PRINCETON, N.J., April 18, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release first quarter 2025 financial results on Monday, May 5, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the conf

      4/18/25 4:30:00 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Integra LifeSciences to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

      PRINCETON, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, announced today that Mojdeh Poul, chief executive officer and Lea Knight, chief financial officer will present at the 35th Annual Oppenheimer Healthcare MedTech & Services Conference on March 17, 2025 at 10:00am ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website at https://investor.integralife.com/events-and-presentations. About Integra LifeSciencesAt Integra LifeSciences, we are driven by our purpose of restoring patients' lives. We innovate treatment pathways to advance pati

      3/13/25 5:00:00 PM ET
      $IART
      Medical/Dental Instruments
      Health Care

    $IART
    Financials

    Live finance-specific insights

    See more
    • Integra LifeSciences Reports First Quarter 2025 Financial Results

      PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2025. First Quarter 2025 Highlights First quarter revenues of $382.7 million increased 3.7% on a reported basis and decreased 3.5% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $(0.33), compared to $(0.04) in the prior year; adjusted earnings per diluted share of $0.41, compared to $0.55 in the prior year.Reaffirming full-year 2025 revenue guidance range and updating adjusted EPS guidance to account for the impact

      5/5/25 6:30:00 AM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Integra LifeSciences to Host First Quarter 2025 Financial Results Conference Call on May 5, 2025

      PRINCETON, N.J., April 18, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release first quarter 2025 financial results on Monday, May 5, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the conf

      4/18/25 4:30:00 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Integra LifeSciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides 2025 Financial Guidance

      PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Reported revenues were $442.6 million, representing an increase of 11.5% on a reported basis and an increase of 3.5% on an organic basis compared to the fourth quarter 2023. GAAP earnings per diluted share were $0.25, compared to $0.25 in the fourth quarter 2023. Adjusted earnings per diluted share were $0.97, compared to $0.89 in the fourth quarter 2023. Full-Year 2024 Reported revenues were $1,610.5 million, representing an increase of 4.5% on a reported basis and

      2/25/25 6:00:00 AM ET
      $IART
      Medical/Dental Instruments
      Health Care